AI Article Synopsis

  • * The results indicate that the rs3769768 AA genotype is associated with an increased risk of EOC, while genotypes rs10190853 GA and rs11869256 GA are linked to a reduced risk, suggesting that these genetic variants may have protective or harmful effects based on the specific genotype.
  • * The findings suggest potential applications for these genetic markers in molecular therapy and prognosis for EOC, although no significant interactions among the SNPs were observed in the study.

Article Abstract

: The potential relation of methyltransferase-like gene polymorphisms and epithelial ovarian cancer (EOC) remains unclear. Five SNPs ( rs3769767 A>G, rs1056321 T>C, rs10190853 G>A, rs3769768 G>A and rs11869256 A>G) of methyltransferase-like genes was selected trough NCBI dbSNP database. Two hundred and eighty-eight cases and 361 controls were enrolled from three hospitals in South China to conduct the case-control study. Genomic DNA was abstracted from peripheral blood and genotyped through a TapMan assay. Stratified analysis was conducted to explore the association of rs10190853, rs3769768, rs11869256 genotype and EOC susceptibility. The combination analysis was adopted to evaluate the relation between inferred haplotypes of the genes and EOC risk. Multifactor dimensionality reduction (MDR) analysis was performed to verify the interaction of SNPs. Among the five analyzed SNPs, rs3769768 AA exhibited a significant association with increased EOC risk, while rs10190853 GA, rs11869256 GA was certified to decrease the susceptibility of EOC. The stratified analysis further revealed the harmful effect of rs3769768 AA in EOC patients. On the contrary, rs11869256 AG/GG and rs10190853 AA showed the reduced risk of EOC in patients of specific subgroups. Combination analysis identified that haplotypes AAA highly connected with reduced risk of EOC. MDR analysis revealed that these SNPs existed no specific interactions. : rs3769768 was related to increased risk of EOC. rs10190853 and rs11869256 decreased the susceptibility in EOC. and could be potential target of molecular therapy and prognosis markers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10869976PMC
http://dx.doi.org/10.7150/jca.90379DOI Listing

Publication Analysis

Top Keywords

risk eoc
12
eoc
10
gene polymorphisms
8
polymorphisms epithelial
8
epithelial ovarian
8
ovarian cancer
8
south china
8
case-control study
8
stratified analysis
8
combination analysis
8

Similar Publications

The measurement of Calcitonin (Ctn) in fine-needle aspiration (FNA) washout fluids (FNA-Ctn) has demonstrated excellent sensitivity, significantly higher than FNA cytology, in detecting medullary thyroid carcinoma (MTC). However, the absence of a fixed cutoff value for FNA-Ctn poses a limitation. This study aimed to investigate whether the sensitivity of FNA-Ctn in detecting MTC varies with different cutoffs reported in the literature.

View Article and Find Full Text PDF

Budd-Chiari Syndrome as an Initial Manifestation of Incomplete Systemic Lupus Erythematosus.

Eur J Case Rep Intern Med

December 2024

Department of Internal Medicine, Ospedale Regionale di Lugano EOC, Lugano, Switzerland.

Unlabelled: This article describes a case of a 26-year-old female with a history of Evan's syndrome who presented with severe exertional dyspnoea and abdominal discomfort. The patient was diagnosed with chronic Budd-Chiari syndrome, a rare vascular disorder characterized by obstruction of the hepatic vein. We discuss the risk factors, the clinical manifestations, and diagnostic methods for Budd-Chiari syndrome, as well as the possible association with an underlying incomplete systemic lupus erythematosus.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzes how clinical risk stratification can be used to assess the advantages of long-term androgen deprivation therapy (ltADT) compared to short-term therapy (stADT) in high-risk localized prostate cancer patients.
  • Results indicate that patients with very-high risk features have greater improvements in survival outcomes when treated with ltADT, although the variation in treatment effects across different risk groups is not statistically significant.
  • The findings suggest the need for further clinical trials to refine risk stratification methods and better identify which high-risk localized prostate cancer patients could benefit more from longer therapy.
View Article and Find Full Text PDF

Introduction: Niraparib was approved for first-line (1L) maintenance (1LM) treatment of patients with advanced epithelial ovarian cancer (EOC) following the PRIMA/ENGOT-OV26/GOG-3012 (PRIMA) trial. PRIMA was restricted to patients at higher risk of progression (excluded stage III EOC with no visible residual disease [NVRD] after primary cytoreductive surgery [PCS]). This retrospective study evaluated the potential impact of excluding stage III EOC with NVRD from PRIMA by assessing real-world treatment outcomes following 1LM niraparib monotherapy in this patient population.

View Article and Find Full Text PDF

Background: The benefit of cytoreduction with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for epithelial ovarian cancer (EOC) remains uncertain. This study investigated the relationship between serum cytokines, particularly monocyte chemoattractant protein-1 (MCP-1), a key inflammatory mediator, and recurrence risk in EOC patients undergoing CRS/HIPEC.

Methods: From January 2018 to January 2023, serum cytokine levels were analyzed in 34 EOC patients (17 primary, 17 recurrent) before and after CRS/HIPEC using MILLIPLEX Magnetic Bead Panels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!